REDCARE PHARMACY NV

RedCare Pharmacy NV’s stock slump: insider sales hit €70, while analysts warn of weak earnings yet market optimism offers a chance for recovery.

Redcare Pharmacy NV sees share price slide yet remains a key player in Europe’s online pharmacy market, offering a broad health & beauty product range and home‑delivery.

Redcare Pharmacy NV’s new German pharmacy‑hour regulation could boost online sales and cut costs—exploring how this shift fuels growth amid volatile small‑cap markets.

Redcare Pharmacy NV’s Q2 earnings beat and upgraded guidance lift its target price, sparking a rally and boosting investor confidence amid MDAX volatility.

Redcare Pharmacy NV’s recent share dip reflects broader market swings, yet the Dutch online pharmacy’s robust product mix and European reach keep investors eyeing future growth.

Redcare Pharmacy NV, Europe’s leading online pharmacy, ships 100k+ packages daily to millions across Europe, trading on Xetra with a €930 m market cap.

Redcare Pharmacy NV reports a 58% rise in adjusted EBITDA and strong Q1 revenue growth, confirming its 2026 targets and boosting investor confidence in the European online pharmacy market.

Redcare Pharmacy NV’s stock drops as Swiss OTC liberalisation looms; investors weigh the promise of market share gains against rising margin pressure.

Redcare Pharmacy NV’s March 4, 2026 report will reveal if German e‑prescription growth turns into profit, reshaping its €1.3 bn valuation and MDAX outlook.

Redcare Pharmacy’s new PoPP e‑Prescription integration boosts German market entry, slashes fulfillment time, and signals a 134% upside for investors.